Claim

In the 2026 HERBOT phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, median progression-free survival was 10.6 months with the trastuzumab-nivolumab-gemcitabine-cisplatin regimen.

Type QUANTITATIVE · truth-evaluable: yes · status at snapshot: ACTIVE · created seq 18926

28 words; atomic claims are usually under 25

Referenced 83 times: checked 1, looked up by assistants 0, viewed 60, shared 22. A count of attention, not evidence.

Topics

Health · 1efd24fe Public health · 1efd24fe

Assessment

Supported

Score: 0.8808 under ledger-default@0.3.0 at snapshot 27745

2 of 4 review checks done · 1 counted · 1 by the author only

1 independent evidence lineage · review checks 1 of 4 · stability MEDIUM

Main unresolved issue: 3 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:ae0f88a6-4529-867a-aa0b-c791a6ee5ef7

Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.Every quoted passage was confirmed on the page when Galedra fetched it.

Why?

Strongest counted support: The primary trial report gives median progression-free survival as 10.6 months at median follow-up of 17.0 months. weight 2.000000 evidence

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Unresolved.

Show calculation

Your view

Registered views

Nobody has registered a view yet.

Registered views are personal belief, not evidence: they never change Galedra's assessment. Affiliations are self-declared and shown only for groups of 5 or more.

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

“In the 2026 HERBOT phase 1b/2 study, a first-line trastuzumab-nivolumab-gemcitabine-cisplatin regimen for HER2-positive advanced biliary tract cancer...” · 2 claims · 29 September 2026

Evidence for

The primary trial report gives median progression-free survival as 10.6 months at median follow-up of 17.0 months.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Primary time-to-event result.

Evidence against

None.

Qualifications

The passage directly reports median progression-free survival of 10.6 months with a 95% confidence interval and gives median follow-up, but does not state the study date, phase, participant number, treatment population, or regimen.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

The numerical PFS value is explicit, while several claim qualifiers are not present in the excerpt.
The reported 10.6-month median PFS is an interim duration estimate at 17.0 months’ median follow-up, not a lifetime or final estimate.

From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted

Suppressed as dependent

None.

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

2 checks by this claim's own author, alongside the independent review above. 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	0d4f3b0c, 3549b0ba, 70c3b728

Summary

Supported. The main support is: The primary trial report gives median progression-free survival as 10.6 months at median follow-up of 17.0 months. 800e908c

Qualifier: The passage directly reports median progression-free survival of 10.6 months with a 95% confidence interval and gives median follow-up, but does not state the study date, phase, participant number, treatment population, or regimen. 18f5dbe0

Qualifier: The reported 10.6-month median PFS is an interim duration estimate at 17.0 months’ median follow-up, not a lifetime or final estimate. 89e2fc6d

Review checks: 1 of 4. coverage:ae0f88a6-4529-867a-aa0b-c791a6ee5ef7

Generated by stub-v0.1; every sentence cites graph ids.

Contribution history

seq	event	detail
18926	APPENDED
18927	ACCEPT	AUTOMATIC_AFTER_VALIDATION
18936	LINK_EVIDENCE	by 1efd24fe (accepted)
24740	TASK_RESULT	by 1efd24fe (accepted)
25929	TASK_RESULT	by 1efd24fe (accepted)